NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q1 2025 (March 31)4holders −1
0new positions
1sold out
$0.08avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Truist Financial Corp. ($4K), Wolverine Asset Management LLC ($1K) and Virtu Financial LLC ($1K).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $2 |
All 13F filers, Q4 2024 → Q1 2025: 15,088 shares bought and 14,443 shares sold, net +645 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Truist Financial Corp. | — | No change | 38,965 | $4K |
| Wolverine Asset Management LLC | — | Add +290.7% | 20,278 | $1K |
| Virtu Financial LLC | — | Reduce -45.3% | 13,967 | $1K |
| UBS Group AG | — | Reduce -73.6% | 1,032 | $73 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.